NRXP
NRX Pharmaceuticals
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
consensus rating "Strong Buy"
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About NRXP
Nrx Pharmaceuticals, Inc.
A clinical stage pharmaceutical company that develops novel therapies to treat central nervous system disorders
1201 Orange Street, Suite 600, Wilmington, Delaware 19801
--
NRX Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware on May 20, 2015, is a clinical-stage small molecule pharmaceutical company that develops novel therapies for the treatment of central nervous system diseases and life-threatening lung diseases.
Company Financials
EPS
NRXP has released its 2024 Q4 earnings. EPS was reported at -0.35, versus the expected -0.37, beating expectations. The chart below visualizes how NRXP has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
